Alps Advisors Inc Annexon, Inc. Transaction History

Alps Advisors Inc

$17.8 Billion
Q3 2025

A detailed history of Alps Advisors Inc transactions in Annexon, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 47,879 shares of ANNX stock, worth $136,933. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,879

Previous 59,201 19.12%

Holding current value

$136,933

Previous $142,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 05, 2025	SELL	$2.05 - $3.37 $23,210 - $38,155	-11,322 Reduced 19.12%	47,879 $142,000
Q2 2025 Aug 11, 2025	SELL	$1.38 - $2.73 $32,326 - $63,950	-23,425 Reduced 28.35%	59,201 $142,000
Q1 2025 Apr 30, 2025	SELL	$1.93 - $5.5 $6,886 - $19,624	-3,568 Reduced 4.14%	82,626 $159,000
Q4 2024 Feb 13, 2025	BUY	$4.44 - $7.63 $52,614 - $90,415	11,850 Added 15.94%	86,194 $442,000
Q3 2024 Nov 12, 2024	BUY	$4.49 - $7.2 $14,668 - $23,522	3,267 Added 4.6%	74,344 $440,000
Q2 2024 Aug 13, 2024	BUY	$4.33 - $6.79 $307,763 - $482,612	71,077 New	71,077 $348,000
Q2 2022 Aug 11, 2022	SELL	$2.11 - $4.06 $83,952 - $161,539	-39,788 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.73 - $11.94 $12,615 - $55,174	-4,621 Reduced 10.41%	39,788 $109,000
Q4 2021 Feb 09, 2022	SELL	$11.49 - $22.0 $29,575 - $56,628	-2,574 Reduced 5.48%	44,409 $510,000
Q3 2021 Nov 15, 2021	SELL	$16.35 - $23.4 $55,688 - $79,700	-3,406 Reduced 6.76%	46,983 $874,000
Q2 2021 Aug 11, 2021	BUY	$17.81 - $27.48 $897,428 - $1.38 Million	50,389 New	50,389 $1.13 Million

Others Institutions Holding ANNX

# of Institutions

154

Shares Held

101M

Call Options Held

88.6K

Put Options Held

32.5K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $136M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Annexon, Inc. Transaction History